[18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy

[(18)F]Fluorodeoxyglucose (FDG) PET is a functional imaging tool that provides metabolic information, which has the potential to detect a lesion before it becomes anatomically apparent. This ability constitutes a strong argument for using FDG-PET/computed tomography (CT) in the management of oncolog...

Full description

Saved in:
Bibliographic Details
Published inPET clinics Vol. 9; no. 4; p. 469
Main Authors Samim, Morsal, El-Haddad, Ghassan E, Molenaar, Izaak Quintes, Prevoo, Warner, van den Bosch, Maurice A A J, Alavi, Abass, Lam, Marnix G E H
Format Journal Article
LanguageEnglish
Published United States 01.10.2014
Subjects
Fluorodeoxyglucose F18
Humans
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Multimodal Imaging
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Staging
Positron-Emission Tomography
Radiopharmaceuticals
Tomography, X-Ray Computed
FDG-PET
Interventional oncology
Staging
Imaging
Liver
Radiofrequency ablation
Radioembolization
Chemoembolization
Online AccessGet more information

Cover

More Information
Summary:[(18)F]Fluorodeoxyglucose (FDG) PET is a functional imaging tool that provides metabolic information, which has the potential to detect a lesion before it becomes anatomically apparent. This ability constitutes a strong argument for using FDG-PET/computed tomography (CT) in the management of oncology patients. Many studies have investigated the accuracy of FDG-PET or FDG-PET/CT for these purposes, but with small sample sizes based on retrospective cohorts. This article provides an overview of the role of FDG-PET or FDG-PET/CT in patients with liver malignancies treated by means of surgical resection, ablative therapy, chemoembolization, radioembolization, and brachytherapy, all being liver-directed oncologic interventions.
ISSN:1879-9809
DOI:10.1016/j.cpet.2014.07.004